SyntheMed Enrolls First Patient in European Study for REPEL-CV

SyntheMed announced the enrollment of the first patient in its multicenter European clinical study for REPEL-CV Adhesion Barrier. The initial patient was enrolled at the Clinic for Heart and Vascular Surgery of the German Heart Center in Munich under the direction of Rudiger Lange.

()a href="http://today.reuters.com/stocks/QuoteCompanyNewsArticle.aspx?view=PR&symbol=SYMD&storyID=142472%2B08-Jun-2005%2BPRN" target="_blank">Reuters